AgomAb Therapeutics NV

我们掌握的 AgomAb Therapeutics NV 最新季度

取自公司自己的 6-K 文件。

管理层说了什么

“In the first half of 2026, we continued to execute on our clinical and operational strategy, and we are on track with the clinical read-outs and trial initiations of ontunisertib and AGMB-447 expected later this year,”

逐字引自公告，且只在文件将其归于具名人士时才展示。

AgomAb Therapeutics NV 做什么

Crohn’s Disease Crohn’s disease is a chronic progressive disease of the gastrointestinal tract. It is estimated that approximately 46% of patients with Crohn’s disease have fibrosis of the gastrointestinal tract, resulting in stricture formation and intestinal obstructions, most frequently in the terminal ileum. These strictures can cause obstructive symptoms leading to dietary change, malnutrition and surgery. Despite the large unmet medical need, there are no approved pharmacological therapies for FSCD.

公司自己的描述，取自公告末尾。